These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 31602329)

  • 21. Retrospective analysis of efficacy and safety of Gemcitabine-based chemotherapy in patients with metastatic pancreatic adenocarcinoma experiencing disease progression on FOLFIRINOX.
    de Jesus VHF; Camandaroba MPG; Donadio MDS; Cabral A; Muniz TP; de Moura Leite L; Sant'Ana LF
    J Gastrointest Oncol; 2018 Oct; 9(5):806-819. PubMed ID: 30505579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gemcitabine plus nab-paclitaxel for pancreatic cancer and interstitial lung disease: A nationwide longitudinal study.
    Saito K; Michihata N; Hamada T; Jo T; Matsui H; Fushimi K; Nakai Y; Yasunaga H; Fujishiro M
    Cancer Sci; 2023 Oct; 114(10):3996-4005. PubMed ID: 37547944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Albumin-bound paclitaxel: a review of its use for the first-line combination treatment of metastatic pancreatic cancer.
    Hoy SM
    Drugs; 2014 Oct; 74(15):1757-68. PubMed ID: 25260887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-Line Gemcitabine, Nab-Paclitaxel, and Oxaliplatin Chemotherapy With Itraconazole in Patients With Metastatic Pancreatic Cancer: A Single Institution Experience.
    Sawasaki M; Tsubamoto H; Sugihara A; Ikuta S; Sakai Y; Osaki Y; Sonoda T
    Anticancer Res; 2022 Dec; 42(12):6063-6069. PubMed ID: 36456160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multi-center, Phase II trial of nab-paclitaxel and gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
    Tachihara M; Kiriu T; Hata A; Hatakeyama Y; Nakata K; Nagano T; Yamamoto M; Kobayashi K; Ohnishi H; Katakami N; Nishimura Y
    Cancer Manag Res; 2019; 11():7135-7140. PubMed ID: 31534366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between Low-Grade Chemotherapy-Induced Peripheral Neuropathy (CINP) and Survival in Patients with Metastatic Adenocarcinoma of the Pancreas.
    Catalano M; Aprile G; Ramello M; Conca R; Petrioli R; Roviello G
    J Clin Med; 2021 Apr; 10(9):. PubMed ID: 33922821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients.
    Yang SH; Guo JC; Hsu C; Kuo SH; Tien YW; Cheng AL; Yeh KH
    J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):97-105. PubMed ID: 30852003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes of first line FOLFIRINOX
    Patel T; Miccio J; Cecchini M; Srikumar T; Stein S; Kortmanksy J; Johung K; Lacy J
    J Gastrointest Oncol; 2021 Dec; 12(6):2547-2556. PubMed ID: 35070386
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Kim G
    Cancer Manag Res; 2017; 9():85-96. PubMed ID: 28356771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment outcomes of gemcitabine plus nab-paclitaxel in pancreatic cancer patients with malignant ascites.
    Inoue K; Fukushi K; Yamaguchi S; Taira T; Shibuki T; Satake T; Watanabe K; Sasaki M; Imaoka H; Mitsunaga S; Ikeda M
    Pancreatology; 2024 Jun; 24(4):616-623. PubMed ID: 38599956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial.
    Guo X; Lou W; Xu Y; Zhuang R; Yao L; Wu J; Fu D; Zhang J; Liu J; Rong Y; Jin D; Wu W; Xu X; Ji Y; Wu L; Lv M; Yao X; Liu X; Wang D; Kuang T; Liu L; Wang W; Liu T; Zhou Y
    Oncol Lett; 2024 Apr; 27(4):161. PubMed ID: 38449794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Folfirinox
    Williet N; Saint A; Pointet AL; Tougeron D; Pernot S; Pozet A; Bechade D; Trouilloud I; Lourenco N; Hautefeuille V; Locher C; Desrame J; Artru P; Thirot Bidault A; Le Roy B; Pezet D; Phelip JM; Taieb J
    Therap Adv Gastroenterol; 2019; 12():1756284819878660. PubMed ID: 31598136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Usefulness of the G8 Geriatric Assessment Tool as a Prognostic Factor in Gemcitabine Plus Nab-paclitaxel Combination Therapy for Elderly Patients with Pancreatic Cancer.
    Kadokura M; Mori Y; Takenaka Y; Yoda H; Yasumura T; Tanaka K; Amemiya F
    JMA J; 2022 Oct; 5(4):512-519. PubMed ID: 36407075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarcinoma.
    Pignon F; Turpin A; Hentic O; Coriat R; Salmon E; Baumgaertner I; Bertrand N; Lévy P; Rebours V; Hammel P; de Mestier L
    Pancreatology; 2021 May; ():. PubMed ID: 34090806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-1 inhibitors plus nab-paclitaxel-containing chemotherapy for advanced gallbladder cancer in a second-line setting: A retrospective analysis of a case series.
    Tan S; Yu J; Huang Q; Zhou N; Gou H
    Front Oncol; 2022; 12():1006075. PubMed ID: 36465365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: A Retrospective Monocentric Study.
    Zhang F; Wang Y; Yang F; Zhang Y; Jiang M; Zhang X
    Cancer Manag Res; 2022; 14():535-546. PubMed ID: 35173487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AGIG Chemo-Immunotherapy in Patients With Advanced Pancreatic Cancer: A Single-Arm, Single-Center, Phase 2 Study.
    Dai W; Qiu X; Lu C; Zou Z; Sha H; Kong W; Liu B; Du J
    Front Oncol; 2021; 11():693386. PubMed ID: 34722242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of relative dose intensity of nab-paclitaxel for the short-term outcomes, survival, and quality of life in patients with advanced pancreatic cancer: a retrospective study.
    Lian L; Shen XM; Huang TA; Li DP; Li XM; Han SG; Xu XF; Ma CT; Zhou C
    Transl Cancer Res; 2022 Jul; 11(7):2310-2320. PubMed ID: 35966303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel: A retrospective study.
    Tozuka Y; Ueno M; Kobayashi S; Morimoto M; Fukushima T; Sano Y; Kawano K; Hanaoka A; Tezuka S; Asama H; Moriya S; Morinaga S; Ohkawa S; Maeda S
    Oncol Lett; 2022 Oct; 24(4):375. PubMed ID: 36238838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis.
    Zhang Y; Xu J; Hua J; Liu J; Liang C; Meng Q; Ni Q; Shi S; Yu X
    J Cancer; 2019; 10(18):4420-4429. PubMed ID: 31413762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.